Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
An Updated View On Fulcrum Therapeutics
02:10pm, Monday, 25'th Sep 2023
Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the c
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
08:00am, Friday, 22'nd Sep 2023
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
09:46am, Thursday, 24'th Aug 2023
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
Options Traders Blast Biotech Stock on FDA Buzz
02:59pm, Tuesday, 22'nd Aug 2023
Fulcrum Therapeutics Inc (NASDAQ:FULC) is up 49.7% to trade at $5.87 at last glance -- its highest levels since March -- after the U.S. Food and Drug Administration (FDA) lifted its clinical hold on t
Why Is Fulcrum Therapeutics (FULC) Stock Up 43% Today?
09:39am, Tuesday, 22'nd Aug 2023
Fulcrum Therapeutics (NASDAQ: FULC ) stock is on the rise Tuesday as investors react to positive news from the FDA. The big news here is the FDA lifted its clinical hold on the Investigational New Dru
Fulcrum Therapeutics shares skyrocket as FDA lifts clinical hold on sickle cell disease trial
08:54am, Tuesday, 22'nd Aug 2023
Fulcrum Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for its sickle cell disease therapeutic F
Fulcrum Utility Services to cancel listing as shares plummet
04:48am, Monday, 21'st Aug 2023
Fulcrum Utility Services Ltd (AIM:FCRM), the energy infrastructure group, shed more than two-thirds of its value on Monday after it announced it would be cancelling its AIM listing subject to sharehol
Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Call Transcript
05:18am, Saturday, 05'th Aug 2023
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alexander Sapir - President and Chief
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
09:48am, Thursday, 03'rd Aug 2023
Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.83 per share a year ago.
Fulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCD
02:15pm, Wednesday, 24'th May 2023
Crisis of confidence in prior management (related to full clinical hold in February for FTX-6058 in SCD) led to currently cheap valuation. New CEO (appointed mid May) sold prior companies to Pfizer an
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates
09:55am, Monday, 15'th May 2023
Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.64 per share a year ago.
5 Best and Worst Performing Small-Cap Stocks in February 2023
10:51pm, Monday, 13'th Mar 2023
Small-cap stocks, in general, are more domestic in nature, and this protects them from geopolitical and foreign exchange risks.
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
09:53am, Thursday, 09'th Mar 2023
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically
